Case | Removal rate (%) | Tumor volume at GK (ml) | Marginal dose (Gy) | Isodose (%) | PF period (months) | Overall survival (months) | Treatment and clinical course |
---|---|---|---|---|---|---|---|
1 | 100 | 6.6, 3.1,1.0, 1.1, 7.7, 3.2 | 14, 14, 15, 15, 14, 5 × 5 | 50, 50, 50, 50, 50, 50 | 12 | 186 | TS - GK × 6 - |
2 | 100 | N/A | N/A | N/A | 169 | 169 | TS - |
3 | 75 | 1.2 | 20 | 90 | 51 | 224 | TS – GK – GK – GK - TS - GK – TC - CK died from disease progression to sarcoma |
4 | 100 | 7.3, 17.6, 27.8 | 14, 14, 15 | 50, 50, 50 | 48 | 62 | TS - GK - GK - TS - TS - GK died from epistaxis |
5 | 90 | 2.7 | 16 | 50 | 6 | 165 | TS – TS – GK |
6 | 70 | 13.0, 3.2 | 13, 12 | 50 | 31 | 100 | TS - FR(50Gy) - TS - GK - TS - GK died from brain stem invasion |
7 | 100 | N/A | N/A | N/A | 69 | 150 | TS - |
8 | 100 | N/A | N/A | N/A | 152 | 152 | TS - |
9 | 100 | N/A | N/A | N/A | 138 | 138 | TS - |
10 | 100 | 1.0 | 18 | 52 | 95 | 130 | TS – GK |
11 | 100 | 2.3 | 16 | 55 | 30 | 127 | TS – GK |
12 | 95 | 4.5 | 17 | 50 | 38 | 38 | TS – GK died from lung cancer |
13 | 100 | N/A | N/A | N/A | 115 | 115 | TS - |
14 | 80 | 14.5 | 16 | 50 | 21 | 62 | TS – GK |
15 | 95 | 1.7 | 16 | 50 | 24 | 60 | TS – GK |
16 | 73 | N/A | N/A | N/A | 15 | 51 | TS - |
17 | 91 | 17.6 | 15 | 50 | 19 | 45 | TS – GK |
18 | 95 | N/A | N/A | N/A | 27 | 27 | TS - |
19 | 100 | N/A | N/A | N/A | 27 | 27 | TS - |